AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 125 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 2.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,113,000 | +108.8% | 68,729 | -2.0% | 0.01% | +75.0% |
| Q3 2019 | $1,970,000 | -22.9% | 70,118 | +3.8% | 0.00% | -20.0% |
| Q2 2019 | $2,556,000 | +15.0% | 67,524 | +18.6% | 0.01% | 0.0% |
| Q1 2019 | $2,222,000 | +79.0% | 56,955 | -2.2% | 0.01% | +66.7% |
| Q4 2018 | $1,241,000 | -37.0% | 58,222 | +17.0% | 0.00% | -25.0% |
| Q3 2018 | $1,970,000 | +5.2% | 49,762 | +1.6% | 0.00% | 0.0% |
| Q2 2018 | $1,872,000 | +103.7% | 49,000 | +60.3% | 0.00% | +100.0% |
| Q1 2018 | $919,000 | +13.6% | 30,567 | +18.0% | 0.00% | 0.0% |
| Q4 2017 | $809,000 | +16.9% | 25,901 | +4.8% | 0.00% | 0.0% |
| Q3 2017 | $692,000 | +33.8% | 24,714 | -8.5% | 0.00% | +100.0% |
| Q2 2017 | $517,000 | +157.2% | 27,000 | +128.8% | 0.00% | – |
| Q1 2017 | $201,000 | -6.9% | 11,800 | 0.0% | 0.00% | – |
| Q4 2016 | $216,000 | -0.5% | 11,800 | -3.3% | 0.00% | – |
| Q3 2016 | $217,000 | – | 12,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |